Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension

NCT00216255 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT00216255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00216255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Double-blind, Randomized, Multicenter, Flexible-dose, Placebo Controlled Pilot Study of Pagoclone in Patients With PDS Followed by a 52-week Open-label Extension
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2005
Completion date
July 31, 2011
Enrollment
120 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

persistent developmental stuttering